Although surgical and catheter-based revascularization techniques have substan tially improved today’s therapeutic potential in ischemic heart disease, in the majority of patients treatment will be conservative for a number of reasons, the cost-effectiveness of non-pharmacological approaches being of major importance. During the last two decades, drug development for ischemic heart disease has been impressive and many new compounds have been added to our therapeutic armamentarium. Nevertheless, where mode of action is concerned, it is interesting to note that, despite all these efforts, we are still confined to three categories of drugs. Antithrombotics and platelet-active agents aside, these concern nitrates, betablocking drugs and calcium antagonists, agents which reduce ischemia by diminishing cardiac work or wall stress,. thereby affecting myocardial oxygen demand and/or by improving coronary blood flow. Alone or in combination, these agents have proved to be efficacious in the treatment of angina pectoris or other symptoms of ischemic heart disease in a number of patients, but certainly not in all. Moreover, as side-effects are often a problem with current antianginal compounds, the physician may find himself restricted in his therapeutic capabilities and in need of new and, preferably, alternative forms of pharmacological treatment.
"Sinopsis" puede pertenecer a otra edición de este libro.
Although surgical and catheter-based revascularization techniques have substan tially improved today's therapeutic potential in ischemic heart disease, in the majority of patients treatment will be conservative for a number of reasons, the cost-effectiveness of non-pharmacological approaches being of major importance. During the last two decades, drug development for ischemic heart disease has been impressive and many new compounds have been added to our therapeutic armamentarium. Nevertheless, where mode of action is concerned, it is interesting to note that, despite all these efforts, we are still confined to three categories of drugs. Antithrombotics and platelet-active agents aside, these concern nitrates, betablocking drugs and calcium antagonists, agents which reduce ischemia by diminishing cardiac work or wall stress,. thereby affecting myocardial oxygen demand and/or by improving coronary blood flow. Alone or in combination, these agents have proved to be efficacious in the treatment of angina pectoris or other symptoms of ischemic heart disease in a number of patients, but certainly not in all. Moreover, as side-effects are often a problem with current antianginal compounds, the physician may find himself restricted in his therapeutic capabilities and in need of new and, preferably, alternative forms of pharmacological treatment.
This volume addresses a novel concept in antiischemic therapy, sinus node inhibition. The sinus node inhibitors which have thus far been developed, including the clonidine-derivative alinidine, falipamil and the benzazepinone derivative UL FS 49, are discussed in detail.
"Sobre este título" puede pertenecer a otra edición de este libro.
Librería: BuchWeltWeit Ludwig Meier e.K., Bergisch Gladbach, Alemania
Taschenbuch. Condición: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -Although surgical and catheter-based revascularization techniques have substan tially improved today's therapeutic potential in ischemic heart disease, in the majority of patients treatment will be conservative for a number of reasons, the cost-effectiveness of non-pharmacological approaches being of major importance. During the last two decades, drug development for ischemic heart disease has been impressive and many new compounds have been added to our therapeutic armamentarium. Nevertheless, where mode of action is concerned, it is interesting to note that, despite all these efforts, we are still confined to three categories of drugs. Antithrombotics and platelet-active agents aside, these concern nitrates, betablocking drugs and calcium antagonists, agents which reduce ischemia by diminishing cardiac work or wall stress, thereby affecting myocardial oxygen demand and/or by improving coronary blood flow. Alone or in combination, these agents have proved to be efficacious in the treatment of angina pectoris or other symptoms of ischemic heart disease in a number of patients, but certainly not in all. Moreover, as side-effects are often a problem with current antianginal compounds, the physician may find himself restricted in his therapeutic capabilities and in need of new and, preferably, alternative forms of pharmacological treatment. 76 pp. Englisch. Nº de ref. del artículo: 9783798508613
Cantidad disponible: 2 disponibles
Librería: GreatBookPrices, Columbia, MD, Estados Unidos de America
Condición: New. Nº de ref. del artículo: 18677032-n
Cantidad disponible: 15 disponibles
Librería: Kennys Bookshop and Art Galleries Ltd., Galway, GY, Irlanda
Condición: New. This volume addresses a novel concept in antiischemic therapy, sinus node inhibition. The sinus node inhibitors which have thus far been developed, including the clonidine-derivative alinidine, falipamil and the benzazepinone derivative UL FS 49, are discussed in detail. Editor(s): Hjalmarson, A.; Remme, W. J. Num Pages: 64 pages, 3 black & white illustrations, biography. BIC Classification: MJD; MMG. Category: (P) Professional & Scholarly; (UP) Postgraduate. Dimension: 244 x 170 x 4. Weight in Grams: 137. . 1991. Paperback. . . . . Nº de ref. del artículo: V9783798508613
Cantidad disponible: 15 disponibles
Librería: moluna, Greven, Alemania
Condición: New. Nº de ref. del artículo: 5316945
Cantidad disponible: Más de 20 disponibles
Librería: Ria Christie Collections, Uxbridge, Reino Unido
Condición: New. In English. Nº de ref. del artículo: ria9783798508613_new
Cantidad disponible: Más de 20 disponibles
Librería: AHA-BUCH GmbH, Einbeck, Alemania
Taschenbuch. Condición: Neu. nach der Bestellung gedruckt Neuware - Printed after ordering - Although surgical and catheter-based revascularization techniques have substan tially improved today's therapeutic potential in ischemic heart disease, in the majority of patients treatment will be conservative for a number of reasons, the cost-effectiveness of non-pharmacological approaches being of major importance. During the last two decades, drug development for ischemic heart disease has been impressive and many new compounds have been added to our therapeutic armamentarium. Nevertheless, where mode of action is concerned, it is interesting to note that, despite all these efforts, we are still confined to three categories of drugs. Antithrombotics and platelet-active agents aside, these concern nitrates, betablocking drugs and calcium antagonists, agents which reduce ischemia by diminishing cardiac work or wall stress, thereby affecting myocardial oxygen demand and/or by improving coronary blood flow. Alone or in combination, these agents have proved to be efficacious in the treatment of angina pectoris or other symptoms of ischemic heart disease in a number of patients, but certainly not in all. Moreover, as side-effects are often a problem with current antianginal compounds, the physician may find himself restricted in his therapeutic capabilities and in need of new and, preferably, alternative forms of pharmacological treatment. Nº de ref. del artículo: 9783798508613
Cantidad disponible: 1 disponibles
Librería: preigu, Osnabrück, Alemania
Taschenbuch. Condición: Neu. Sinus node inhibitors | A new concept in angina pectoris | W. J. Remme (u. a.) | Taschenbuch | viii | Englisch | 1991 | Steinkopff | EAN 9783798508613 | Verantwortliche Person für die EU: Steinkopff, Dietrich Verlag in Springer Science + Business M, Tiergartenstr. 15-17, 69121 Heidelberg, juergen[dot]hartmann[at]springer[dot]com | Anbieter: preigu Print on Demand. Nº de ref. del artículo: 102112532
Cantidad disponible: 5 disponibles
Librería: Books Puddle, Woodside, NY, Estados Unidos de America
Condición: New. pp. 76. Nº de ref. del artículo: 261537254
Cantidad disponible: 4 disponibles
Librería: Revaluation Books, Exeter, Reino Unido
Paperback. Condición: Brand New. 1st edition. 76 pages. Delaware language. 9.61x6.69x0.18 inches. In Stock. Nº de ref. del artículo: x-3798508615
Cantidad disponible: 2 disponibles
Librería: buchversandmimpf2000, Emtmannsberg, BAYE, Alemania
Taschenbuch. Condición: Neu. This item is printed on demand - Print on Demand Titel. Neuware -Although surgical and catheter-based revascularization techniques have substan tially improved today's therapeutic potential in ischemic heart disease, in the majority of patients treatment will be conservative for a number of reasons, the cost-effectiveness of non-pharmacological approaches being of major importance. During the last two decades, drug development for ischemic heart disease has been impressive and many new compounds have been added to our therapeutic armamentarium. Nevertheless, where mode of action is concerned, it is interesting to note that, despite all these efforts, we are still confined to three categories of drugs. Antithrombotics and platelet-active agents aside, these concern nitrates, betablocking drugs and calcium antagonists, agents which reduce ischemia by diminishing cardiac work or wall stress, thereby affecting myocardial oxygen demand and/or by improving coronary blood flow. Alone or in combination, these agents have proved to be efficacious in the treatment of angina pectoris or other symptoms of ischemic heart disease in a number of patients, but certainly not in all. Moreover, as side-effects are often a problem with current antianginal compounds, the physician may find himself restricted in his therapeutic capabilities and in need of new and, preferably, alternative forms of pharmacological treatment.Steinkopff Dr. Dietrich V, Poststr. 9, 64293 Darmstadt 76 pp. Englisch. Nº de ref. del artículo: 9783798508613
Cantidad disponible: 1 disponibles